Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years old, of any gender, at the time of signing the consent form
• People with an expected survival time of more than 3 months
• People who are generally well enough to carry out light activity and care for themselves (a measure of physical fitness used in cancer trials, known as ECOG score 0–1)
• People who have been diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC) that can be surgically removed, and who have already received pre-surgery treatment that included a type of immunotherapy drug called a PD-1 antibody
• People whose lung cancer does not have certain gene mutations known as "driver gene mutations" (confirm with trial site)
• People who have not had their cancer come back after surgery, including no local return of cancer
• People who are expected to complete standard follow-up (adjuvant) treatment after surgery
• People who have tumour tissue available for surgical removal or biopsy
• People whose blood counts and organ function (such as liver and kidneys) are at acceptable levels
• People who are willing to sign a written consent form to take part

Who may not be able to join:

• People who have had another type of cancer in the past 5 years, unless it was a cancer considered fully treated and cured, such as certain thyroid cancers, cervical carcinoma in situ, certain skin cancers, or breast ductal carcinoma in situ treated with surgery
• People who still have side effects from previous cancer treatments that have not settled down to a mild level (Grade 1 or below), with some exceptions such as hair loss, certain nerve-related effects, or some long-term hormone-related conditions (confirm with trial site)
• People who had a severe immune-related side effect (Grade 3 or higher) during previous immunotherapy that caused that treatment to be permanently stopped
• People who have received any vaccine within the two months before signing the consent form, or who plan to receive a vaccine during the study
• People who have received certain types of cell therapies (TIL cell therapy, allogeneic T cell therapy, or NK cell therapy) in the six months before signing the consent form
• People who have previously received a bone marrow or stem cell transplant from a donor, or a solid organ transplant
• People who currently have or are suspected of having an active autoimmune disease (a condition where the immune system attacks the body)
• People with significant fluid build-up around the lungs or in the abdomen that is causing symptoms or needing treatment
• People with current or permanent scarring or damage to the lung tissue (irreversible interstitial lung disease)
• People with serious heart or blood vessel conditions
• People with an active infection currently requiring treatment throughout the body
• People with infectious diseases such as hepatitis B, hepatitis C, syphilis, or HIV/AIDS
• People with certain conditions affecting the veins in the oesophagus or stomach that may increase the risk of bleeding, or who show signs of increased pressure in the liver's blood supply — these individuals may need an internal examination (endoscopy) within 3 months before joining (confirm with trial site)
• People with uncontrolled conditions such as diabetes, or other significant non-cancer illnesses that could affect safety or the reliability of study results
• People known to be allergic to any ingredient in the study drug or the LM103 product
• People who are pregnant or breastfeeding
• People who, in the view of the trial doctors, have other serious medical, mental health, or laboratory conditions that could increase risk or affect the study results

Important: Always verify eligibility with the trial site directly before applying.